Causes, diagnosis, and treatment of central precocious puberty

Lancet Diabetes Endocrinol. 2016 Mar;4(3):265-274. doi: 10.1016/S2213-8587(15)00380-0. Epub 2016 Feb 4.

Abstract

Central precocious puberty results from the premature activation of the hypothalamic-pituitary-gonadal axis. It mimics physiological pubertal development, although at an inappropriate chronological age (before 8 years in girls and 9 years in boys). It can be attributable to cerebral congenital malformations or acquired insults, but the cause in most cases in girls remains unknown. MKRN3 gene defects have been identified in familial disease, with important basic and clinical results. Indeed, genetic analysis of this gene should be included in the routine clinical investigation of familial and idiopathic cases of central precocious puberty. Gonadotropin-releasing hormone agonists are the gold-standard treatment. The assessment and management of this disease remain challenging for paediatric endocrinologists. In this Series paper, we describe current challenges involving the precise diagnosis and adequate treatment of this disorder.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Child
  • Female
  • Gonadotropin-Releasing Hormone / agonists
  • Humans
  • Hypothalamo-Hypophyseal System / pathology
  • Hypothalamo-Hypophyseal System / physiopathology
  • Male
  • Pituitary-Adrenal System / pathology
  • Pituitary-Adrenal System / physiopathology
  • Puberty, Precocious / diagnosis*
  • Puberty, Precocious / etiology*
  • Puberty, Precocious / physiopathology
  • Puberty, Precocious / therapy*
  • Ribonucleoproteins / genetics
  • Ubiquitin-Protein Ligases

Substances

  • Ribonucleoproteins
  • Gonadotropin-Releasing Hormone
  • MKRN3 protein, human
  • Ubiquitin-Protein Ligases